Top 10 Ayahuasca Papers

In a double-blind randomised placebo-controlled trial of people with treatment-resistant depression, a single dose of ayahuasca produced rapid antidepressant effects versus placebo over the first week. 49 and higher response rates over the first week. The first controlled trial of a psychedelic in this population supports the safety and therapeutic potential of ayahuasca when dosed in an appropriate setting. For readers, the value is not just the result but the study design: it shows how ayahuasca research performs when tested under more structured clinical conditions.

The open-label study found that a single dose of ayahuasca has fast-acting anxiolytic and antidepressant effects in patients with a current depressive episode. It adds a concrete angle on ayahuasca research, helping readers understand the topic through evidence rather than broad claims alone. Together with the other papers here, it helps separate what is distinctive about ayahuasca research from claims that apply to psychedelics more broadly.

The open-label study found that a single dose of ayahuasca had significant antidepressant effects over the following weeks. It adds a concrete angle on ayahuasca research, helping readers understand the topic through evidence rather than broad claims alone. Together with the other papers here, it helps separate what is distinctive about ayahuasca research from claims that apply to psychedelics more broadly.

The open-label study investigated the effects of ayahuasca on the communication between brain networks of experienced users, and found a decrease in the activity of core structures of the Default Mode Network (DMN). Its main value is mechanistic: it helps connect subjective or clinical effects to biology instead of treating the drug experience as a black box. Together with the other papers here, it helps separate what is distinctive about ayahuasca research from claims that apply to psychedelics more broadly.

The paper investigated the alkaloid composition of field samples, consisting of the bark and leaf specimens used for brewing ayahuasca, which were also compared directly with other ayahuasca mixtures. Their compositions were generally similar, with little variation in the constituents of brews made by different ayahuasqueros. It adds a concrete angle on ayahuasca research, helping readers understand the topic through evidence rather than broad claims alone. Together with the other papers here, it helps separate what is distinctive about ayahuasca research from claims that apply to psychedelics more broadly.

This double-blind, placebo-controlled clinical study investigated the subjective and cardiovascular effects and alkaloid pharmacokinetic properties of orally ingested ayahuasca in healthy volunteers. The time course of DMT plasma concentrations closely paralleled subjective effects. The pharmacokinetic results indicated a predominantly harmine-DMT interaction in the gastrointestinal tract and possibly in the liver. Its main value is mechanistic: it helps connect subjective or clinical effects to biology instead of treating the drug experience as a black box.

The observational study investigated the impact of ayahuasca-assisted group therapy within the context of a retreat ceremony, on self-reported and qualitative measures of mental health and addiction. Participants exhibited improved mindfulness, personal empowerment, and hopefulness, and reported less frequent use of cocaine, alcohol, and tobacco up to 4 weeks after the ceremony. Their intake of cannabis, sedatives, and opiates (e. methadone) did not change, however, these were not identified as the substances of primary concern by the majority of participants.

The paper discusses ayahuasca as a possible therapeutic agent and details the challenges that need to be overcome for clinical studies using ayahuasca in the United States to become viable. It adds a concrete angle on ayahuasca research, helping readers understand the topic through evidence rather than broad claims alone. Together with the other papers here, it helps separate what is distinctive about ayahuasca research from claims that apply to psychedelics more broadly.

The longitudinal field study assessed personality, mental health, life attitudes, and neuropsychological performance in a large number of long-term ritual ayahuasca users and control participants that were matched for age, sex, educational level, and religious background. Long-term ayahuasca use indicated a lower presence of psychopathological symptoms, better performance in neuropsychological tests, higher degrees of spirituality, and better psychosocial adaptation as reflected by some attitudinal traits such as Purpose in Life and Subjective Well-Being, and benefits on mental health were still observable in a one-year follow-up.

The review (1990–2015) found preliminary evidence from six small clinical trials that ayahuasca, psilocybin and LSD have antidepressive, anxiolytic and antiaddictive effects and were well tolerated, including in treatment‑resistant cases; however, many studies were open‑label and underpowered, so larger randomised, double‑blind, placebo‑controlled trials are needed to confirm efficacy. That makes it useful as a map of ayahuasca research: it shows where evidence clusters, where the field is thin, and which claims need more cautious reading. Together with the other papers here, it helps separate what is distinctive about ayahuasca research from claims that apply to psychedelics more broadly.